Rationale Assays of schedule-controlled responding can be used to characterize the pharmacology of benzodiazepines and other GABA A receptor modulators, and are sensitive to changes in drug effects that are related to physical dependence. Objective The present study used this approach to investigate the role of GABA A receptor subtypes in mediating dependencelike effects following benzodiazepine administration. Methods Squirrel monkeys (n=6) were trained on a fixed-ratio schedule of food reinforcement. Initially, the response ratedecreasing effects of chlordiazepoxide (0.1-10 mg/kg; nonselective GABA A receptor agonist), zolpidem (0.032-1.0 mg/kg; α1 subunit-containing GABA A subtype-preferring agonist), and HZ-166 (0.1-10 mg/kg; functionally selective α2 and α3 subunit-containing GABA A receptor agonist) were assessed. Next, acute dependence-like effects following single injections of chlordiazepoxide, zolpidem, and HZ-166 were assessed with flumazenil (0.1-3.2 mg/kg; nonselective GABA A receptor antagonist). Finally, acute dependence-like effects following zolpidem administration were assessed with βCCt and 3-PBC (0.1-3.2 mg/kg and 0.32-10 mg/kg, respectively; α1 subunitcontaining GABA A receptor antagonists).
Introduction
The γ-aminobutyric acid type A (GABA A ) receptors are the primary sites of action for benzodiazepines and related drugs used to treat anxiety and sleep disorders. The therapeutic use of benzodiazepine-type drugs for the treatment of these disorders is constrained, however, by other characteristic effects such as daytime drowsiness, motor impairments, and reinforcing effects that are thought to contribute to their abuse (Griffiths and Weerts, 1997; Licata and Rowlett, 2008) . In addition, benzodiazepines have also the propensity to produce physical dependence which can be observed following not only chronic treatment but may also manifest following a single drug administration (e.g., Lukas and Griffiths, 1984; Spealman, 1986; Bronson, 1994) .
Benzodiazepines bind to a specific site on GABA A receptors where they induce a conformational change, leading to an allosteric enhancement in the ability of GABA to increase chloride conductance. Over the past two decades, research has revealed the existence of multiple subtypes of the GABA A receptor (e.g., Pritchett et al., 1989; Rudolph et al., 2001; Olsen and Sieghart, 2008) ; and subsequent reports have provided evidence to support the notion that the diverse behavioral effects of benzodiazepine-type drugs may reflect their action at these different subtypes (Rudolph et al., 1999; McKernan et al., 2000; Löw et al., 2000; Rowlett et al., 2005) . These observations raise the possibility for a pharmacological dissociation between the clinically advantageous effects and unwanted side-effects of these compounds.
GABA A receptors in the central nervous system are pentamers constituted from structurally distinct proteins, with each protein family consisting of different subunits (for review, see Rudolph et al., 2001 ). The majority of GABA A receptors are composed of α, β, and γ subunits; and benzodiazepines bind to a site on the native GABA A receptor that is located at the interface of the γ2 subunit and one of the α1, α2, α3, or α5 subunits. Studies in rodent models have suggested a differential anatomical distribution among these GABA A subunitcontaining receptors. In this regard, GABA A receptors containing α1 subunits (α1GABA A receptors) are ubiquitously located, and have been implicated in the sedative, operant ratereducing, and reinforcing effects of benzodiazepines (Rudolph et al., 1999; Licata et al., 2005; Fischer et al., 2010; Tan et al., 2010) . In contrast, GABA A receptors containing α2 and α3 subunits (α2GABA A and α3GABA A receptors, respectively) are anatomically distributed in the cortex, limbic system, and spinal cord, and have been associated with the anxiolytic and antihyperalgesic effects of benzodiazepines (McKernan et al., 2000; Löw et al., 2000; Rowlett et al., 2005 , Fischer et al., 2010 Knabl et al., 2008) . Finally, GABA A receptors containing α5 subunits (α5GABA A receptors) are a relatively minor population expressed primarily within the hippocampus and are thought to play a role in certain memory processes associated with benzodiazepines (Collinson et al., 2002; Crestani et al., 2002; Atack et al., 2006) .
The contribution that the different GABA A receptor subtypes have in benzodiazepine-induced physical dependence is less clear. Limited data is available to delineate a role of the GABA A receptor subtypes following repeated administration (e.g., Mirza and Nielsen, 2006) ; and the role of these receptors in acute physical dependence following a single administration has yet to be addressed. In the Mirza and Nielsen (2006) study, the GABA A receptor inverse agonist FG-7142 precipitated withdrawal in mice following chronic administration of a series of conventional benzodiazepines, but failed to do so following chronic administration of the α1GABA A receptor-sparing compounds SL651498 and L-838,417. Together, these findings raise the possibility that α1GABA A receptors may play a key role in benzodiazepine-induced physical dependence following chronic treatment.
The current study was designed to assess further the physical dependence-like effects that follow benzodiazepine administration, particularly the role that GABA A receptor subtypes play in dependence following a single drug administration. Towards this end, squirrel monkeys were trained in an operant conditioning procedure in which behavior was maintained by the presentation of food pellets. This approach was chosen as it is an established method commonly used to quantify changes in behavior related to dependence (e.g., Holtzman and Villarreal, 1973; McMahon and France, 2002) , and is a particularly sensitive measure of acute dependence (e.g., Spealman 1986; Bronson, 1994) . Moreover, this approach has been shown to be advantageous in delineating receptor subtype mechanisms in other systems (e.g., opioid receptor subtypes, Adams and Holtzman 1990) . Initial studies established a model of physical dependence-like effects as evident from an increased potency of the nonselective GABA A receptor antagonist flumazenil following a single injection of the nonselective benzodiazepine chlordiazepoxide. Subsequent studies assessed the role of the GABA A receptor subtypes that mediate this effect by administering the α1GABA A -preferring agonist zolpidem and the α2GABA A /α3GABA A agonist HZ-166 as pretreatment. Finally, the role of α1GABA A receptors was examined further by assessing the rate-decreasing effects of the α1GABA A -preferring antagonists βCCT and 3-PBC following zolpidem pretreatment.
Materials and methods
Subjects Six adult squirrel monkeys (Saimiri sciureus) were maintained on a 12-h lights-on/12-h lights-off cycle (lights on at 7:00 AM). Water was available continuously in the home cage and food was available in the home cage after the session. Monkeys were prepared with a chronic indwelling polyvinyl chloride catheter according to previously described procedures (Platt et al., 2011) . In brief, under isoflurane anesthesia and aseptic conditions, one end of a catheter was passed to the level of the right atrium by way of a femoral or jugular vein. The distal end of the catheter was passed subcutaneously and exited the skin in the midscapular region. Catheters were flushed daily with heparinized 0.9 % saline solution and sealed with stainlesssteel obturators when not in use. Monkeys wore nylon-mesh jackets (Lomir Biomedical, Toronto, Canada) at all times to protect the catheter.
Squirrel monkeys weighed between 0.7 and 1.2 kg throughout the study. Two of the six monkeys were experimentally naïve, two monkeys had previous experience discriminating methamphetamine from vehicle, one monkey had previous experience discriminating a benzodiazepine from vehicle, and one monkey had previous experience selfadministrating intravenous cocaine. Animals in this study were maintained in accordance with the guidelines of the Committee on Animals of Harvard Medical School and the Guide for Care and Use of Laboratory Animals (8th edition, 2011). Research protocols were approved by the Harvard Medical School Institutional Animal Care and Use Committee.
Operant conditioning behavior Rates of responding were assessed in an experimental operant chamber during daily sessions, typically 5 days each week (Monday through Friday). Monkeys sat in a Plexiglas chair facing a panel equipped with stimulus lights, a response lever, and a food pellet receptacle (MED Associates, St. Albans, VT). The operant conditioning chamber was controlled by a MED-PC interface and an IBM-compatible computer programmed with MED Associates software (MED Associates).
Monkeys were trained under a multiple-cycle procedure consisting of a 7-min pretreatment period followed by a 3-min response period. During the pretreatment period, stimulus lights were not illuminated and responding had no scheduled consequences. During the response period, the stimulus lights were illuminated and monkeys could obtain up to 10 food pellets (Bioserve, Frenchtown, NJ) under a fixed-ratio 10 schedule of food presentation. If all 10 reinforcers were earned before 3-min had elapsed, the light was turned off and responding had no scheduled consequences for the remainder of the response period. Training sessions consisted of five consecutive cycles, and testing began once response rates were stable throughout the session.
Test sessions were conducted in lieu of training sessions once or twice per week if responding was stable throughout the five preceding training sessions, defined as the average rates of responding for each cycle not varying by more than 20 %, with no upward or downward trends. Test sessions were identical to training sessions, except that cumulative doses of drug were administered i.v. 2 min into the pretreatment period of each cycle (i.e., 5-min pretreatment time; 10-min inter-injection interval), increasing in one-half log unit increments. The first series of tests assessed the cumulative dose-effect curves and time-course of chlordiazepoxide, zolpidem, or HZ-166 alone. Next, doses of chlordiazepoxide, zolpidem, or HZ-166 were given as a pre-session pretreatment, followed by dose-effect curves for flumazenil, βCCT, and 3-PBC via cumulative dosing. During test sessions in which a pretreatment was administered, the pretreatment time was based upon the duration of action of each compound.
Drugs Chlordiazepoxide hydrochloride and flumazenil were purchased from Sigma-Aldrich (St. Louis, MO) and zolpidem L-tartaric acid salt was a gift from Dr. K. Fang (Sepracor, Inc.; Marlborough, MA) and dissolved in 50 % propylene glycol and 50 % sterile water. -(2′-pyridine)-4H-2,5,10b-triaza-benzo[e]azulene-3-carboxylic acid ethyl ester), βCCT (β-carboline-3-carboxylate-tert-butyl ester), and 3-PBC (3-propoxy-β-carboline hydrochloride) were synthesized at the Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee and dissolved in 20 % ethanol, 60 % propylene glycol, and 20 % sterile water. Pretreatment doses of chlordiazepoxide (1.0-10 mg/kg), zolpidem (0.1-1.0 mg/kg) and HZ-166 (1.0-10 mg/kg) were chosen based upon the preliminary dose-effect curves as determined in the present or previous studies (Spealman, 1986; McMahon and France 2002; Fischer et al., 2010) .
Data analysis The number of responses on the lever per second were recorded and expressed as a percentage of control responding using the average rate of responding from the previous day as the control value (average of five cycles) for individual animals. Data are expressed graphically as the mean (± the standard error of the mean, SEM) percent control response rate from the group. Rates of responding during time-course experiments were considered to have returned to baseline if they were within 10 % of the control baseline response rates (i.e., a minimum of 90 % control). To compare changes in the behavioral effects following antagonist (flumazenil, βCCT, and 3-PBC) administration, a two-way analysis of variance was conducted. Additional Bonferroni t tests were also conducted to compare individual doses versus the antagonist alone control. For all tests, the level of statistical significance was set at p<0.05. If significant antagonist-induced rate-decreasing effects were detected, potency values (dose reducing responding to 75 % of control, ED 75 ) were calculated by log-linear regression from the descending limb of the group dose-effect curve.
Results
Figure 1 (top) shows the rate-decreasing effects of chlordiazepoxide, zolpidem, and HZ-166. Chlordiazepoxide, zolpidem, and HZ-166 produced statistically significant decreases in schedule-controlled responding across the dose ranges studied, resulting in ED 75 values (mg/kg, i.v.) of 3.5 (±0.42 SEM), 0.21 (±0.044 SEM), and 3.2 (±1.5 SEM), respectively. When assessed over time (Fig. 1, bottom) , operant responding returned to baseline values (i.e., ≥ 90 % control) at 100 min following administration of zolpidem, 300 min following administration of HZ-166, and 1,440 min following administration of chlordiazepoxide, and these values were used as pretreatment times during subsequent experiments.
Figure 2 (top) shows the rate-decreasing effects of flumazenil alone and following the 1,440 min pretreatment with chlordiazepoxide. Flumazenil was without effect across the dose range tested. Flumazenil did, however, suppress schedule-controlled responding in a dose-dependent manner following chlordiazepoxide pretreatment [F(3,36)= 17; p<0.001]. In this regard, flumazenil did not decrease rates of responding following pretreatment doses of 1.0 mg/kg chlordiazepoxide and 3.2 mg/kg chlordiazepoxide, whereas flumazenil did decrease rates of responding following a pretreatment dose of 10 mg/kg chlordiazepoxide, resulting in a flumazenil ED 75 value of 0.074 (±0.057 SEM). Bonferroni t tests revealed that flumazenil doses of 0.32-3.2 mg/kg suppressed response rates following pretreatment of 10 mg/kg chlordiazepoxide. Figure 2 (middle) also shows the rate-decreasing effects of flumazenil alone and following pretreatment with zolpidem (100 min pretreatment). Flumazenil suppressed schedulecontrolled responding in a dose-dependent manner following zolpidem pretreatment [F(3,28)=12; p<0.001]. Here, flumazenil did not decrease rates of responding following 0.1 and Points above "V' indicate average rates of responding (±SEM) following vehicle administration. Asterisks represent significant differences relative to vehicle (Bonferroni t tests, p<0.05). Time-course data were determined following the highest dose tested for each drug (10 mg/kg chlordiazepoxide, 1 mg/kg zolpidem, and 10 mg/kg HZ-166) Fig. 2 Effects of flumazenil on schedule-controlled responding, either alone or following pretreatment with chlordiazepoxide (top), zolpidem (middle), or HZ-166 (bottom). Pretreatment times for each GABA A receptor agonist were 1,440 min, 100 min, or 300 min, respectively. Abscissae, dose of flumazenil in milligrams per kilogram; ordinates, mean (±SEM) response rate as percentage of control. Points above "V" indicate mean (±SEM) rates of responding following vehicle administration, either alone or following GABA A receptor agonist pretreatment. Asterisks represent significant differences relative to vehicle (Bonferroni t tests, p<0.05) 0.32 mg/kg zolpidem, but significant decreases in response rates were observed following 1.0 mg/kg zolpidem, resulting in an ED 75 value of 0.34 (±0.12 SEM). Bonferroni t tests revealed that flumazenil doses of 1.0 and 3.2 mg/kg decreased response rates following this dose of zolpidem. Also shown in Fig. 2 (bottom) are the effects of flumazenil following 300-min pretreatment with HZ-166 on operant behavior. In contrast to zolpidem, pretreatment with HZ-166 failed to affect the flumazenil dose-response curve across all doses tested, and an ED 75 value could not be calculated. Figure 3 shows the rate-decreasing effects of βCCT (top) and 3-PBC (bottom) alone and following pretreatment with zolpidem. βCCT and 3-PBC were ineffective when administered alone. Following zolpidem pretreatment, however, both βCCT [F(3,32)=5.9; p=0.002] and 3-PBC [F(3,32)= 6.1; p=0.002] were effective, depending on the pretreatment dose. In this regard, βCCT and 3-PBC did not decrease rates of responding following pretreatment doses of 0.1 and 0.32 mg/kg zolpidem, whereas both GABA A receptor antagonists did decrease rates of responding following a pretreatment dose of 1.0 mg/kg zolpidem. The resulting ED 75 values for βCCT and 3-PBC were 0.16 (±0.060 SEM) and 1.3 (±0.30 SEM), respectively. Bonferroni t tests revealed that the βCCT dose of 1.0 mg/kg decreased response rates following 1.0 mg/kg zolpidem. Further, Bonferroni t tests showed that the 3-PBC doses of 3.2 and 10 mg/kg decreased response rates following 1.0 mg/kg zolpidem.
Discussion
Conventional benzodiazepines bind non-selectively across α1GABA A , α2GABA A , α3GABA A , and α5GABA A receptors; however, the role of these receptor subtypes in benzodiazepine-induced physical dependence is understood poorly. In the present study, we used an assay of schedulecontrolled responding to characterize the role of α1GABA A , α2GABA A , and α3GABA A receptors on an endpoint related to acute physical dependence. Initial studies demonstrated that chlordiazepoxide, zolpidem, and HZ-166 produced dose-dependent decreases in rates of responding, whereas the GABA A receptor antagonists flumazenil, βCCT, and 3-PBC were ineffective over the dose ranges tested. Flumazenil suppressed rates of responding following pretreatment of the non-selective benzodiazepine chlordiazepoxide, as well as pretreatment with the α1GABA Apreferring agonist zolpidem. In contrast, flumazenil did not suppress rates of responding following pretreatment with the α2GABA A /α3GABA A agonist HZ-166. Further, the α1GABA A -preferring antagonists βCCT and 3-PBC decreased response rates following zolpidem pretreatment. Together, these findings raise the possibility that α1GABA A receptors, but not α2GABA A or α3GABA A receptors, play an important role in behaviors that are related to the initiation of physical dependence following conventional benzodiazepine administration. Moreover, these data suggest that the receptor profile that underpins benzodiazepine-induced physical dependence may be different from receptors that mediate other behavioral effects, including antihyperalgesia and anxiolysis.
The positive GABA A receptor modulators that decreased responding did so with a potency ranking of zolpidem > chlordiazepoxide = HZ-166, whereas the GABA A receptor antagonists lacked effects. The finding that zolpidem and chlordiazepoxide reduced rates of responding is consistent with a number of studies demonstrating that various positive GABA A modulators with activity at α1GABA A receptors decrease responding maintained under a variety of operant Fig. 3 Effects of βCCT (top panel) and 3-PBC (bottom panel) on schedule-controlled responding, either alone or following pretreatment with zolpidem. The pretreatment time for zolpidem prior to both GABA A receptor antagonists was 100 min. Abscissae, dose of drug in milligrams per kilogram; ordinates, mean (±SEM) response rate as percentage of control. Points above "V" indicate mean (±SEM) rates of responding following vehicle administration, either alone or following zolpidem pretreatment. Asterisks represent significant differences relative to vehicle (Bonferroni t tests, p<0 .05) schedules (e.g., Paronis and Bergman 1999; Vanover et al., 1999; Rowlett et al., 2005; Fischer et al., 2010) . Further, flumazenil, βCCT, and 3-PBC, compounds that do not substantially modify GABA-mediated chloride flux at α1GABA A receptors (Smith et al., 2001; Harvey et al., 2002) , failed to alter rates of responding, consistent with previous studies (McMahon and France, 2002) . In contrast, the observation that HZ-166 reduced rates of responding, albeit not completely, was unexpected considering the relatively low intrinsic efficacy of HZ-166 at α1GABA A receptors, and contrasts previous observations that this and related compounds do not alter response rates under a similar schedule following i.v. administration in rhesus monkeys (Fischer et al., 2010) . The reasons for this discrepancy are unclear. One possibility is that weak activity at α1GABA A receptors is sufficient for rate-reducing effects in squirrel monkeys; however, this is unlikely since SH-053-2′ F-R-CH 3 , a compound with a similar pharmacological profile to that of HZ-166 at α1GABA A receptors (Fischer et al., 2010; Savić et al. 2010) , does not produce rate decreasing effects in this species across a similar dose range (unpublished). Therefore, the results from the present study suggest that activation of α2GABA A and α3GABA A receptors is sufficient for modest behavioral disruption in squirrel monkeys under certain conditions.
The finding that flumazenil suppressed schedulecontrolled responding following pretreatment with chlordiazepoxide is consistent with the findings described by Spealman (1986) . In this study, flumazenil (i.e., Ro 15-1788) did not produce disruptions in behavior when administered alone, but did so following administration with the benzodiazepines chlordiazepoxide and diazepam, as well as the diazepam metabolite N-desmethyldiazepam on responding maintained under both fixed ratio and fixed interval schedules of reinforcement. This alteration of flumazenil potency has been interpreted as a measure of physical dependence, as the rate-decreasing effects of flumazenil are most likely due to the precipitation of withdrawal (Holtzman and Villarreal, 1973; Lukas and Griffiths, 1982; Gerak and France, 1997; McMahon and France, 2002) .
The main purpose of the present study was to test the hypothesis that acute benzodiazepine-induced physical dependence-like effects may be mediated by specific α subunit-containing GABA A receptors. In order to explore GABA A receptor mechanisms in this effect, initial studies examined the rate-decreasing effects of flumazenil following pretreatment with zolpidem and HZ-166. Here, flumazenil decreased response rates following pretreatment with zolpidem in a similar manner to that seen after chlordiazepoxide pretreatment. This observation raises the possibility that α1GABA A receptors may play a substantial role in benzodiazepine-induced physical dependence. In contrast, flumazenil did not decrease response rates following pretreatment with doses as high as 10 mg/kg HZ-166. It is important to note that the doses of HZ-166 administered as pretreatment were behaviorally effective in the initial doseand time-effect determinations. Therefore, the lack of effect from this drug in inducing a dependence-like state is likely not due to insufficient modulation of GABA A -mediated chloride influx at α2GABA A and/or α3GABA A receptors.
The finding that flumazenil suppressed schedulecontrolled responding following zolpidem pretreatment supports further the hypothesis that α1GABA A receptors mediate acute dependence-like effects. However, although zolpidem has preferential (∼10-fold) selectivity for α1GABA A receptors relative to α2GABA A and α3GABA A receptors, it does activate the latter subtypes at higher doses. Therefore, to explore further the role of α1GABA A receptors on this endpoint, we sought to characterize the enhanced effectiveness of two α1GABA A -preferring antagonists, βCCT and 3-PBC, following zolpidem administration. βCCT and 3-PBC have an approximately 10-to 100-fold greater affinity for α1GABA A receptors relative to α2GABA A , α3GABA A and α5GABA A receptors (Harvey et al., 2002) . Although βCCT and 3-PBC were ineffective when administered alone, both drugs decreased rates of operant responding following zolpidem pretreatment. Considering the affinity of these compounds for α1GABA A receptors, this observation provides additional support for a role of this receptor subtype in zolpidem-induced physical dependence, and in turn provides additional evidence to suggest that α1GABA A receptors may play an important role in benzodiazepine-induced physical dependence.
In consideration of evidence suggesting that physical dependence is an α1GABA A receptor-mediated phenomenon, it is perhaps surprising that initial reports following the introduction of zolpidem suggested that it had a reduced propensity to produce dependence. These initial reports demonstrated a lack of withdrawal-like behaviors following long-term administration and drug discontinuation (Perrault et al., 1992; Elliot and White 2000) . Subsequently, these reports were used to suggest that zolpidem was a safer compound relative to conventional benzodiazepines (e.g., Holm and Goa, 2000) . However, these reports have been contrasted by other studies in which zolpidem-induced physical dependence was apparent (e.g., Griffiths et al., 1992; Weerts and Griffiths, 1998; Kliethermes et al., 2004) , and is in concordance with numerous clinical accounts of zolpidem dependence (cf. Victorri-Vigneau et al., 2007) . The extent to which these differences across studies reflect variables such as species and/or methodology used to demonstrate dependence remains to be determined. Regardless, our findings add to the growing empirical support of the presence of physical dependence-like effects associated with zolpidem administration. Taken together with previously described experiments, the data from the present study provides additional evidence that the behavioral effects of benzodiazepines are mediated by different α-subunit-containing GABA A receptor subtypes. Our findings implicate α1GABA A receptors in benzodiazepine-induced physical dependence-like effects, and suggest further that the receptor mechanisms that underpin physical dependence may be different than those that mediate anxiolysis and antihyperalgesia (α2GABA A and α3GABA A receptor subtypes). Further, our findings suggest that it may be difficult to dissociate α1GABA A receptormediated therapeutic effects (e.g., the sedative effects found in sleep aids) from dependence-like effects. These hypotheses should provide an important framework for studying the role of different GABA A receptor subtypes in the abuserelated effects of benzodiazepine-type drugs, which in turn should help guide both the current clinical use of benzodiazepines as well as the development of improved therapeutic agents for treating anxiety-and pain-related disorders.
